Loading...

NVIDIA Inception Drug Discovery AI Startup Showcase
Pre-Recorded Session Available via Conference Live Agenda (Register for Access)

Moderator: Renee Yao, Global Healthcare AI Startups Lead, NVIDIA

Pharma companies’ overall venture investments have grown steadily over the last 5 years — but AI has emerged as a standout area of investment, with pharma incumbent-backed healthcare AI funding growing more than 10x since 2018. In this talk, you will hear about NVIDIA inception program benefits for healthcare AI startups and hear about a few cutting-edge drug discovery AI startups’ latest breakthroughs. 

Accelerating Molecular Discovery through GPU-Enabled Physics-Based Machine Learning
Tom Miller, PhD, CEO, Entos, Inc.

GPU-Enabled Generative Biology and Generative Chemistry for End-to-End Drug Discovery
Alex Zhavoronkov, PhD, Founder & CEO, Insilico Medicine

nference: Making Biomedical Knowledge Computable
Tyler Wagner, PhD, Senior Director, Biomedical Research, nference

Speaker Bios

Renee Yao, Global Healthcare AI Startups Lead, NVIDIA (Moderator)
Renee Yao leads global healthcare AI startups at NVIDIA, managing 1000+ healthcare startups in digital health, medical instrument, medical imaging, genomics, and drug discovery segments. Previously she worked as a senior product manager and product marketing manager for AI Systems at NVIDIA.

Alex Zhavoronkov, PhD, Founder & CEO, Insilico Medicine
Alex Zhavoronkov, PhD, is the founder and CEO of Insilico Medicine (insilico.com), a leader in next-generation artificial intelligence technologies for drug discovery, biomarker development. He is also the founder and CEO of Deep Longevity, Inc, a global company developing a broad range of artificial intelligence-based biomarkers of aging and longevity. Since 2015 he invented critical technologies in the field of generative adversarial networks (GANs) and reinforcement learning (RL) for generation of the novel molecular structures with the desired properties and generation of synthetic biological and patient data. He also pioneered the applications of deep learning technologies for prediction of human biological age using multiple data types, transfer learning from aging into disease, target identification, and signaling pathway modeling. Under his leadership Insilico raised over $50 million in multiple rounds from expert investors, opened R&D centers in 6 countries and regions, and partnered with multiple pharmaceutical, biotechnology, and academic institutions. Prior to founding Insilico, he worked in senior roles at ATI Technologies (acquired by AMD in 2006), NeuroG Neuroinformatics, Biogerontology Research Foundation. Since 2012 he published over 130 peer-reviewed research papers, and 2 books including “The Ageless Generation: How Biomedical Advances Will Transform the Global Economy” (Palgrave Macmillan, 2013). He serves on the editorial boards of Aging Research Reviews, Aging, Trends in Molecular Medicine, Frontiers in Genetics, and co-chairs the Annual Aging Research, Drug Discovery and AI Forum (7th annual in 2020) at Basel Life, one of Europe’s largest industry events in drug discovery. He is the adjunct professor of artificial intelligence at the Buck Institute for Research on Aging. 

 

Tom Miller, PhD, CEO, Entos, Inc.
Tom Miller is a scientist and entrepreneur with a focus on AI-driven methods for molecular simulation and discovery. Following a PhD at Oxford and a postdoc at UC Berkeley, he joined the Caltech faculty in 2008 and was promoted to full professor in 2013. He has published more than 120 peer-reviewed articles and received awards for research excellence from the Sloan Foundation, Dreyfus Foundation, and American Chemical Society. He has mentored dozens of students and postdocs that are now leaders in academics and industry. In 2020, Tom co-founded Entos, Inc. to accelerate molecular and materials discovery via physics-based machine learning. In the past year, Entos has recruited over 25 world-class AI researchers, software engineers, and drug discovery scientists and continues to grow.

 

Tyler Wagner, PhD, Senior Director, Biomedical Research, nference
Dr. Tyler Wagner is the Senior Director of Biomedical Research at nference and has been with the company for over 3 years. Prior to joining nference, Dr. Wagner obtained his PhD in the Weiss lab (MIT) and Densmore lab (BU) where he engineered both an RNA virus and mRNA into multi-functional platforms for regulated gene delivery. He continued with a postdoc in the Weiss lab where he explored in vivo regulatory strategies for RNA therapeutics. At nference, he is currently leading clinical research projects with multiple pharma companies and the Mayo Clinic, ranging from early detection of disease to real-world outcomes assessment, and is working to apply machine learning to outstanding questions in multiple therapeutic areas, including cardiology, oncology, and neuroscience.